Review of remimazolam and sedatives in the intensive care unit

키워드

참고문헌 (62)

1. Keam SJ, "Remimazolam : first approval", Drugs, 80, pp.625~633 (2020)
2. Masui K, "Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!!", J Anesth, 34, pp.479~482 (2020)
3. Kilpatrick GJ, "Remimazolam : non-clinical and clinical profile of a new sedative", anesthetic agent, 2021, pp.12, 690875~
4. Burry L, "Daily sedation interruption versus no daily sedation interruption for critically ill adult patients requiring invasive mechanical ventilation", Cochrane Database Syst Rev, 2014, pp.CD009176~ (2014)
5. Brush DR, "Sedation and analgesia for the mechanically ventilated patient", Clin Chest Med, 30, pp.131~141 (2009)
6. DAS-Taskforce 2015, "Evidence and consensus based guideline for the management of delirium, analgesia, and sedation in intensive care medicine: revision 2015 (DAS-Guideline 2015)-short version", Ger Med Sci, 13 (2015)
7. Martin J, "Practice of sedation and analgesia in German intensive care units : results of a national survey", Crit Care, 9, pp.R117~R123 (2005)
8. Meiser A, "Inhalational anaesthetics in the ICU : theory and practice of inhalational sedation in the ICU, economics, risk-benefit", Best Pract Res Clin Anaesthesiol, 19, pp.523~538 (2005)
9. Shinotsuka CR, "Perceptions and practices regarding delirium, sedation and analgesia in critically ill patients : a narrative review", Rev Bras Ter Intensiva, 25, pp.155~161 (2013)
10. Schweickert WD, "Strategies to optimize analgesia and sedation", Crit Care, 12(Suppl 3), pp.S6~ (2008)
11. Kress JP, "Sedation and analgesia in the intensive care unit", Am J Respir Crit Care Med, 166, pp.1024~1028 (2002)
12. Temesgen N, "Adult sedation and analgesia in a resource limited intensive care unit : a systematic review and evidence based guideline", Ann Med Surg(Lond), 66, pp.102356~ (2021)
13. Barr J, "Propofol : a new drug for sedation in the intensive care unit", Int Anesthesiol Clin, 33, pp.131~154 (1995)
14. Hall RI, "Propofol vs midazolam for ICU sedation : a Canadian multicenter randomized trial", Chest, 119, pp.1151~1159 (2001)
15. Zorrilla-Vaca A, "Infectious disease risk associated with contaminated propofol anesthesia, 1989-2014(1)", Emerg Infect Dis, 22, pp.981~992 (2016)
16. Bennett SN, "Postoperative infections traced to contamination of an intravenous anesthetic, propofol", N Engl J Med, 333, pp.147~154 (1995)
17. Mirrakhimov AE, "Propofol infusion syndrome in adults : a clinical update", Crit Care Res Pract, 2015, pp.260385~ (2015)
18. Kam PC, "Propofol infusion syndrome", Anaesthesia, 62, pp.690~701 (2007)
19. Shafer A, "Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens", Crit Care Med, 26, pp.947~956 (1998)
20. Bauer TM, "Prolonged sedation due to accumulation of conjugated metabolites of midazolam", Lancet, 346, pp.145~147 (1995)
21. Wandel C, "Midazolam is metabolized by at least three different cytochrome P450 enzymes", Br J Anaesth, 73, pp.658~661 (1994)
22. Pandharipande PP, "Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients : the MENDS randomized controlled trial", JAMA, 298, pp.2644~2653 (2007)
23. Riker RR, "Dexmedetomidine vs midazolam for sedation of critically ill patients : a randomized trial", JAMA, 301, pp.489~499 (2009)
24. Jakob SM, "Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation : two randomized controlled trials", JAMA, 307, pp.1151~1160 (2012)
25. Reade MC, "Effect of dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium : a randomized clinical trial", JAMA, 315, pp.1460~1468 (2016)
26. Skrobik Y, "Low-dose nocturnal dexmedetomidine prevents ICU delirium : a randomized, placebo-controlled trial", Am J Respir Crit Care Med, 197, pp.1147~1156 (2018)
27. Pandharipande PP, "Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis : an a priori-designed analysis of the MENDS randomized controlled trial", Crit Care, 14, pp.R38~ (2010)
28. Kawazoe Y, "Effect of dexmedetomidine on mortality and ventilator-free days in patients requiring mechanical ventilation with sepsis : a randomized clinical trial", JAMA, 317, pp.1321~1328 (2017)
29. Wunsch H, "Use of intravenous infusion sedation among mechanically ventilated patients in the United States", Crit Care Med, 37, pp.3031~3039 (2009)
30. Shehabi Y, "Early sedation with dexmedetomidine in critically ill patients", N Engl J Med, 380, pp.2506~2517 (2019)
31. Jalowiecki P, "Sole use of dexmedetomidine has limited utility for conscious sedation during outpatient colonoscopy", Anesthesiology, 103, pp.269~273 (2005)
32. Scott-Warren VL, "Dexmedetomidine : its use in intensive care medicine and anaesthesia", BJA Educ, 16, pp.242~246 (2016)
33. Jerath A, "Volatile anesthetics : is a new player emerging in critical care sedation?", Am J Respir Crit Care Med, 193, pp.1202~1212 (2016)
34. Kim HY, "Volatile sedation in the intensive care unit: a systematic review and meta-analysis", Medicine(Baltimore), 96, pp.e8976~ (2017)
35. Rosenberg H, "Malignant hyperthermia : a review", Orphanet J Rare Dis, 10, pp.93~ (2015)
36. Goudra BG, "Remimazolam : the future of its sedative potential", Saudi J Anaesth, 8, pp.388~391 (2014)
37. Wesolowski AM, "Remimazolam : pharmacologic considerations and clinical role in anesthesiology", Pharmacotherapy, 36, pp.1021~1027 (2016)
38. Wiltshire HR, "A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056). Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation", Anesth Analg, 115, pp.284~296 (2012)
39. Antonik LJ, "A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056). Part I. Safety, efficacy, and basic pharmacokinetics", Anesth Analg, 115, pp.274~283 (2012)
40. Schüttler J, "Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers. Part I. Pharmacokinetics and clinical pharmacodynamics", Anesthesiology, 132, pp.636~651 (2020)
41. Birgenheier NM, "Soft drugs in anesthesia : remifentanil as prototype to modern anesthetic drug development", Curr Opin Anaesthesiol, 33, pp.499~505 (2020)
42. Stafford JA, "Identification and structure-activity studies of novel ultrashort-acting benzodiazepine receptor agonists", Bioorg Med Chem Lett, 12, pp.3215~3218 (2002)
43. Kilpatrick GJ, "CNS 7056 : a novel ultra-short-acting Benzodiazepine", Anesthesiology, 107, pp.60~66 (2007)
44. Nakanishi T, "Remimazolam for induction of anesthesia in elderly patients with severe aortic stenosis : a prospective, observational pilot study", BMC Anesthesiol, 21, pp.306~ (2021)
45. Stöhr T, "Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment", Br J Anaesth, 127, pp.415~423 (2021)
46. Pambianco DJ, "New horizons for sedation : the ultrashort acting benzodiazepine remimazolam", Tech Gastrointest Endosc, 18, pp.22~28 (2016)
47. Zhou J, "Population pharmacokinetic", pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects, 2020, pp.66, 109899~
48. Zinderman CE, "Anaphylactoid reactions to Dextran 40 and 70 : reports to the United States Food and Drug Administration, 1969 to 2004", J Vasc Surg, 43, pp.1004~1009 (2006)
49. Sasaki H, "Ringer’s acetate solution-induced precipitation of remimazolam", Br J Anaesth, 126, pp.e87~e89 (2021)
50. Yamamoto T, "Re-sleeping after reversal of remimazolam by flumazenil", J Anesth, 35, pp.322~ (2021)
51. Rex DK, "A phase III study evaluating the efficacy and safety of remimazolam(CNS 7056)compared with placebo and midazolam in patients undergoing colonoscopy", Gastrointest Endosc, 88, pp.427~437 (2018)
52. Sneyd JR, "Remimazolam for anaesthesia or sedation", Curr Opin Anaesthesiol, 33, pp.506~511 (2020)
53. Pastis NJ, "Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy", Chest, 155, pp.137~146 (2019)
54. Rex DK, "Safety and efficacy of remimazolam in high risk colonoscopy : a randomized trial", Dig Liver Dis, 53, pp.94~101 (2021)
55. Borkett KM, "A Phase IIa, randomized, double-blind study of remimazolam(CNS 7056)versus midazolam for sedation in upper gastrointestinal endoscopy", Anesth Analg, 120, pp.771~780 (2015)
56. Chen SH, "Remimazolam tosilate in upper gastrointestinal endoscopy : a multicenter, randomized, non-inferiority, phase III trial", J Gastroenterol Hepatol, 36, pp.474~481 (2021)
57. Zhu X, "Efficacy and safety of remimazolam in endoscopic sedation : a systematic review and meta-analysis", Front Med(Lausanne), 8, pp.655042~ (2021)
58. Lee A, "Remimazolam : a review in procedural sedation", Drugs, 81, pp.1193~1201 (2021)
59. Doi M, "Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb", III trial, 2020, pp.34, 543~553
60. Sneyd JR, "Current status of perioperative hypnotics, role of benzodiazepines, and the case for remimazolam : a narrative review", Br J Anaesth, 127, pp.41~55 (2021)
61. Whizar-Lugo V, "Remimazolam : a new ultra short acting benzodiazepine", J Anesth Crit Care, 4, pp.1~5 (2016)
62. "REmimazolam infusion in the context of hypnotic shortage in the critical care unit during the pandemic of COVID-19: the non-randomized, non-controlled, pilot, open, mono-centric REHSCU study" (2000)[URL]

관련 논문AI추천